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We report two cases of Ross River virus (RRV) infec-
tion in Dutch travellers who visited Australia during 
February to April 2015. These cases coincided with the 
largest recorded outbreak of RRV disease in Australia 
since 1996. This report serves to create awareness 
among physicians to consider travel-related RRV dis-
ease in differential diagnosis of patients with fever, 
arthralgia and/or rash returning from the South Pacific 
area, and to promote awareness among professionals 
advising travellers to this region.
Case presentation
Case 1
A woman in her early 50s with a history of polymyal-
gia rheumatica visited the outpatient department of a 
hospital in Rotterdam because of persistent joint pains 
after travel to Australia. She had stayed in Australia 
from 30 January until 5 March, where she mainly 
stayed in the surroundings of Perth. From 7 February, 
she stayed in Cairns for six days. She recalled having 
had multiple mosquito bites during her stay in Cairns. 
Seven days after her return to Perth (on 20 February), 
she developed fever, fatigue, frontal headache, mus-
cle aches and arthralgia of her hands, wrists, feet and 
ankles. In addition, she noticed an itchy papular rash 
on her face, neck and trunk. She was treated with pred-
nisone by a local general practitioner for a presumed 
recurrence of her polymyalgia, pending the results of 
serological investigations. Serology for RRV was IgM 
positive, therefore treatment with prednisone was 
discontinued. 
Two months after returning to the Netherlands, she still 
experienced debilitating arthralgia and an unsteady 
gait, frequently necessitating the use of a walking aid. 
In addition, she reported a subfebrile temperature 
and sweating. On physical examination, no abnor-
malities were seen. She had a normal body tempera-
ture of 36.9 °C and her joints did not show any sign of 
arthritis. Laboratory investigation revealed an elevated 
erythrocyte sedimentation rate (ESR) of 32 mm/hr, a 
normal leukocyte count of 6.6 x 109/L, no abnormali-
ties in the differential morphology of the leukocytes 
and a C-reactive protein (CRP) level of 6 mg/L (norm: 
<10 mg/L). Serological testing for RRV on convalescent 
serum (taken 7 April) showed the presence of IgM and 
seroconversion for IgG antibodies specific for RRV 
(Table). RRV aetiology was further confirmed by com-
parative indirect immunofluorescence assay (IIFA) for 
RRV, Barmah Forest virus (BFV), chikungunya virus 
(CHIKV) and Sindbis virus (SINV), and virus neutrali-
zation (Table). BFV, CHIKV and SINV are alphaviruses 
causing symptoms comparable to those caused by 
RRV, which are endemic to the region.
Case 2
A woman in her late 60s visited her general practitioner 
on 11 May 2015 with complaints of fatigue, myalgia, 
arthralgia and a maculopapular rash but no fever. The 
patient had visited Australia from 29 March to 9 May 
2015, where she stayed in New South Wales (in Sydney, 
Armidale and a mangrove forest near Coff Harbour). 
She recalled having been bitten by mosquitoes dur-
ing a trip on 14 April. The first symptoms of wrist 
pains appeared around 21 April, followed by a rash a 
few days later. The patient visited a local physician on 
27 April and treatment with meloxicam was initiated. 
Laboratory investigation revealed a normal erythrocyte 
sedimentation rate of 5 mm/hr. Diagnostics for RRV, 
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BFV, Epstein–Barr virus, B19 parvovirus and connec-
tive tissue disease were negative.
Upon the patient’s return to the Netherlands, the rash 
reappeared (Figure) and the joint pains in her hands 
and knees increased. Treatment with naproxen was 
started. Serology for Borrelia burgdorferi showed IgM 
but no IgG; however, this diagnosis remained inconclu-
sive as it was not confirmed by analysis of a second 
serum sample. Serological testing for RRV and BFV on a 
convalescent serum taken on 20 May showed the pres-
ence of IgM and IgG antibodies specific for RRV (Table). 
A second serum sample taken on 24 June showed 
decreasing IgM and increasing IgG titres. RRV aetiology 
was further confirmed by comparative IIFA for RRV, BFV, 
CHIKV and SINV, and by virus neutralisation (Table).
Background
RRV, an alphavirus transmitted by mosquitoes, is 
endemic in Australia and Papua New Guinea, with occa-
sional epidemics in island countries in the Asia-Pacific 
region. The virus is maintained in an enzootic cycle 
between mosquitoes and marsupials, such as kanga-
roos and wallabies, as primary reservoirs. Rodents, 
rabbits, fruit bats, possums, horses, cats and dogs 
have been implicated as well [1-3]. Human-to-human 
transmission has been described in epidemic situ-
ations, and viraemic travellers from Australia have 
been linked to epidemics in the Cook Islands, Fiji, New 
Caledonia and Samoa [3]. Unnoticed circulation of RRV 
has been described in French Polynesia [4]. Recent evi-
dence supports RRV transmission through blood dona-
tion [5]. Mosquitoes belonging to the genera Aedes and 
Culex are considered the main vector species and verti-
cal transmission has been described as a way for the 
virus to persist during adverse conditions in desicca-
tion-resistant eggs [6].
RRV is endemic in tropical and subtropical Australia 
(Northern Territory and Queensland) with year-round 
notification of human cases, while in temperate 
Australia (New South Wales and Victoria) human cases 
occur seasonally and in epidemics [3,6]. According to 
the Australian Department of Health, by 23 June 2015, a 
total of 7,552 RRV disease cases had been reported this 
year, which is the largest number of annual reported 
cases since 1996 [7]. Most cases up to 23 June were 
reported in Queensland (n = 5,075) and New-South 
Wales (n = 1,292) and peak incidences were in February 
to April.
The incubation period for RRV disease (also called epi-
demic polyarthritis) is typically 7–9 days, ranging from 
3 to 21 days [1]. In 55–75% of infections, the individu-
als are asymptomatic. Symptomatic disease typically 
includes arthralgia, myalgia and fatigue.
Low-grade fever (37.5–38.5 °C) and maculopapular 
rash on the torso and limbs (sometimes palms, soles 
and face) occur in 50–60% of clinical cases [1]. Joint 
pain, stiffness and swelling are usually symmetrical, 
affecting wrists, hands, fingers, ankles and knees. 
Additional manifestations may include headache, 
diarrhoea and nausea. Symptoms most often resolve 
Table
Differential diagnostics for two Dutch travellers returning 
from Australia with Ross River virus disease, February–
April 2015
Antibody tested 
Test results
Case 1
Sample taken
46 days after 
symptom onset
Case 2
Sample taken 
30 days after 
symptom onset
Anti-RRV-IgGa 2.23 3.64
Anti-RRV-IgMa 4.81 6.33
Anti-RRV-IgGb 1:10,240 1:2,560
Anti-RRV-IgMb 1:640 1:5,120
RRV NAbc 1:40 1:40
Anti-BFV-IgG/IgMa,b neg neg
Anti-CHIKV-IgGb 1:160 1:1,280
Anti-CHIKV-IgMb 1:320 neg
CHIKV NAbc neg neg
Anti-SINV-IgG/IgMb neg neg
BFV: Barmah Forest virus; CHIKV: chikungunya virus; NAb: 
neutralising antibodies; neg: negative; RRV: Ross River virus; 
SINV: Sindbis virus.
a Enzyme-linked immunosorbent assay (PanBio ELISA) values < 1.0 
were considered negative.
b Indirect immunofluorescence assay titres < 1:20 for serum were 
considered negative [9].
c Virus neutralisation test titres < 1:20 for serum were considered 
negative [9].
Figure
Rash in a traveller (Case 2) returning from Australia 
with Ross River virus disease, 19 May 2015, 29 days post 
symptom onset 
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within 3–6 months; permanent sequelae have not 
been described.
Treatment of symptomatic cases is supportive. 
Analgesics and nonsteroidal anti-inflammatory drugs 
may be helpful in the treatment of arthritis and arthral-
gia. No vaccine is available [1,3].
Laboratory findings are non-specific. Leukocyte counts 
and CRP levels are usually normal, ESR elevated. 
Diagnostics are most often based on serology as the 
viraemic stage is very short (typically fewer than seven 
days post symptom onset for alphaviruses) and molec-
ular diagnostics are not considered useful on samples 
taken more than a week after symptom onset. Serology 
is complicated by putative cross-reactivity with other 
alphaviruses, especially CHIKV, which belongs to the 
same serogroup [1,3,8].
Discussion
Diagnosis of RRV disease in travellers returning to 
Europe is very rare [8-11]. A history of mosquito bites 
and stay in RRV-affected areas are epidemiological 
parameters supportive of a confirmative diagnosis 
based on RRV IgM and IgG responses. Based on these 
criteria, only three cases of RRV disease have been 
confirmed between 1 January 2009 and 30 June 2015 
in the Netherlands, including the two cases in 2015 
reported here, who had additional confirmation by 
gold-standard serology (virus neutralisation). In this 
period, a total of 56 diagnostic requests for RRV were 
submitted to the Dutch national arbovirus reference 
centre in Rotterdam. Of these, 20 requests indicated 
the travel destination as Australia and/or Asia-Pacific; 
for 30 requests, the travel destination was unknown. 
Although local circulation of RRV is unknown, travel to 
Indonesia, Thailand, Malaysia and the Philippines trig-
gered diagnostic requests as well. Febrile disease and/
or arthralgia were the most common symptoms (in 21 
of 35 diagnostic requests with clinical data), leading to 
RRV disease being considered.
The cases presented here highlight the importance of 
considering RRV in differential diagnosis for travellers 
presenting with acute arthritis returning from Australia 
and the Asia-Pacific region. The two cases we describe 
were related to travel to risk areas in Australia in 
February/March and March–May 2015. Other arbovi-
ruses circulating in Australia and causing polyarthritis 
that should be included in differential diagnosis are the 
alphaviruses BFV and SINV, and the flaviviruses West 
Nile virus (Kunjin virus, KUNV) and Kokobera virus 
(KOKV). Depending on other travel destinations in the 
Asia-Pacific region, chikungunya virus, dengue virus 
and Zika virus should be considered as well [3,12]. The 
annual incidence of RRV disease in Australia ranges 
from 2,000 to 8,000 cases; for BFV disease, from 500 
to 2800. Human cases of KUNV or KOKV disease are 
rare, while the occurrence of human infections with the 
Oceania lineage of SINV is under debate [3,12].
Although RRV-viraemic travellers have been linked to 
the spread and epidemics with RRV in the Asia-Pacific 
region, it is highly unlikely that return of viraemic trav-
ellers to Europe will result in autochthonous transmis-
sion. As the duration of viraemia is short, the likelihood 
that a traveller will be viraemic on their return is small. 
More importantly, the three main vectors for RRV trans-
mission based on field isolations and competence 
studies are either strictly confined to Australia (Ae. 
vigilax and Ae. camptorhynchus, both invasive but not 
established in New Zealand) or the Asia-Pacific region 
(C. annulirostri) [1].
This report underlines the need for awareness of RRV-
related risks among physicians, professionals advis-
ing travellers and travellers themselves. Australia is a 
popular travel destination for Europeans, especially for 
German, British and French tourists [13]. The number 
of leisure travellers from the Netherlands to Australia 
and/or New Zealand has been stable during 2002 to 
2011, averaging to 52,000 travellers per year [14]. In 
January to March 2015, a total of 459,700 Europeans, 
including 12,600 from the Netherlands, had travelled 
to Australia [13]. Infection is preventable using com-
mon mosquito-prevention measures such as wearing 
long trousers, long sleeves, light-coloured clothes and 
insect repellents.
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